the m.14484T>C mutation compared to carriers with different haplogroups.
Before the Spanish arrived in 1520 in what is today Chile, the territory was inhabited by various indigenous groups, including Aymaras, Atacameños, Picunche, Mapuche, Pehuenche, Huilliche, Chonos, Kawéskar, and Yámana [19, 20] . During the early period of the Spanish conquest, most immigrants were male. Other significant additions to the population included slaves of primarily African descent, who were brought to Chile until slavery was abolished in 1823 [21] [22] [23] .
As a consequence of the predominantly male gender of the Spanish emigrants to Chile, asymmetric miscegenation occurred primarily between Spanish men with indigenous women, and to a lesser extent, female slaves of African descent [24] . Thus, there is a peculiar distribution of haplogroups in Santiago's population as a result of this historical occurrence in which female ancestors were mainly Amerindian and male ancestors mainly European [24] .
There are four predominant haplogroup founders in South America, which are designated A, B, C, and D [25] [26] [27] [28] . In Chile, 37 haplogroups have been described that can be grouped into a large number of sub-haplogroups [26] [27] [28] [29] [30] [31] . Studies show that the frequency of haplogroup B decreases from north to south within Chile. In turn, haplogroups C and D increase in frequency from north to south [26] [27] [28] [29] [30] [31] [32] . Because the variety of human mDNA haplogroups is directly related to ethnicity, studies showing the influence of haplogroup background on LHON are often limited to the specific populations in which the study was conducted [2, 4, 13, [33] [34] [35] [36] [37] .
In Latin America, several studies have been conducted in families with LHON, but the families primarily had European haplogroups [36] [37] [38] [39] . No studies to date have correlated South American mitochondrial haplogroups with clinical manifestations in patients with LHON. The main aim of this study was to report the molecular and ophthalmic clinical characteristics of 15 Chilean families with LHON and to relate the characteristics to the mitochondrial haplogroups.
METHODS
Participants: 75 individuals, 26 affected (21 male and 5 female) and 49 healthy (12 male and 37 female) were recruited from six different hospitals throughout Chile. All examinations were performed according to the tenets of the Declaration of Helsinki, and the present study was approved by the ethics committee of the Clinical Hospital of the University of Chile and was adhered to the ARVO Statement. This study was conducted between March 2006 and August 2012. All participants gave written informed consent to participate in the study. Index cases were identified during neuroophthalmic examination at different centers throughout Chile. All patients were referred to the Clinical Hospital of the University of Chile, where a clinical record was obtained, pedigrees were constructed, and genetic testing was performed.
All patients and available relatives were interviewed. Patients were questioned regarding the characteristics of visual loss, as well as previous habits before and after the onset of the disease. Smoking at least one cigarette daily within 6 months of symptom onset as well as during or after the appearance of the disease was considered positive for tobacco exposure. Any history of exposure to alcohol, illegal drugs, or industrial toxins was also recorded.
In each case, the clinical suspicion for LHON was first identified by a neuroophthalmologist who did not know the individual's genetic status. After genetic testing, all individuals with bilateral optic atrophy, low vision, and one of the three most common mutations associated with LHON (m.3460G>A, m.11778G>A, or m.14484T>C) were considered affected. Individuals with the same mutations for LHON as their affected relatives who had no complaints and had no optic atrophy or visual acuity or field deficits on exam were considered unaffected healthy carriers.
Ophthalmologic evaluations: All participants (affected and unaffected) received a detailed clinical examination that included best corrected visual acuity [40, 41] , pupillary exam, red color saturation, biomicroscopy of the anterior segment, and dilated fundus examinations. Optic nerve photography was done with the Zeiss Digital Imaging System, FF 450 plus (Zeiss FF 450 plus, Carl Zeiss AG, Jena, Germany). In all index cases, we also performed the Goldmann visual field examination test using standard Goldmann perimetry (S-940, Haag-Streit, Bern, Switzerland) and whole brain magnetic resonance imaging (MRI) with contrast (Siemens Symphony, Quantum Gradienten, Maestro class 1.5T, Siemens, Erlangen, Germany).
Molecular genetic analysis:
Peripheral blood (5 ml) was collected from affected patients and unaffected relatives and genomic DNA was isolated. Briefly, blood was preserved in EDTA and DNA extraction was completed within 24 h of initial patient blood draw. DNA was isolated from whole blood by a rapid non enzymatic method, involving salting out of the cellular proteins by dehydration and precipitation with saturated sodium chloride solution. DNA was finally precipitated with absolute ethanol and washed with ice-cold 70% ethanol [42] . The mitochondrial DNA was amplified using the technique of chain reaction (PCR) using oligonucleotide pairs specific to the mitochondrial DNA regions where each study mutations: MTND4*LHON11778A (F cccaccttggctatcatc, R ggtaaggcgaggttagcg); MTND1*LHON3460A (F: TTC AAA TTC CTC CCT GTA CG, R: GGC TAC TGC TCG CAG TG). MTND6*LHON14484C (F: ATC CTC CCG AAT CAA CCC TG, R: TTT TTT TAA TTT ATT TAG GGG GCC TG) [43] .
Mutational analysis:
The presence of one of the three primary LHON mutations was determined with restriction fragment length polymorphism analysis. The amplified fragments were digested with restriction enzymes specific for each mutation: 3460A, Hin1I; NmuCI 11778A, 14484C, MvaI [43] in all affected and unaffected subjects. For all patients, the presence of the specific mutation was confirmed with sequencing. Mitochondrial haplogroup was determined with direct sequencing of the regions HV1 and HV2 and compared with the reference sequences [44] .
Pedigree and penetrance calculation:
We determined the penetrance of each primary LHON mutation by counting the total number of affected and unaffected siblings of each index patient in each generation. Penetrance was determined by dividing the number of affected by the total per gender.
Data analysis: Statistical analysis was performed using PASW Statistics 18.0.0 (IBM SPSS, New York, NY). Continuous variables were analyzed with ANOVA with post-hoc Bonferroni correction. The Kruskal-Wallis test was used to compare categorical variables between the haplogroups, significance was set at p<0.05.
RESULTS
We initially identified 36 unrelated suspected cases. Fifteen (41.7%) of these individuals carried at least one of the three most common mutations associated with LHON. After obtaining informed consent, we examined 75 affected and unaffected carriers in the 15 families.
Of 26 affected cases, 21 (80.7%) were men, and five (19.3%) were women. In carrier subjects, 36 (73.5%) were women, and 13 (26.5%) were men. The overall penetrance observed in this study was 61.8% (21 of 34) for the male and 12.2% (five of 36) for the female subjects. The differences in penetrance of the different haplogroups could not be effectively analyzed because of the small size of the groups. The gender ratio in the studied population was 4.2/1 with 21 men and five women affected, and 13 carrier men and 36 carrier women ( Table 1 ).
The mean age of onset of symptoms was 22.2±13.4 years old, ranging between 3 and 53 years. Five of the affected began to note symptoms before age 10, with two of these before 6 years of age; both were female (Table 2 ).
In the affected subjects, the mean time between symptom onset and first examination was 7.8±4.9 days (range 12 h and 21 days). Six patients (23.1%) reported that visual acuity loss was simultaneous in both eyes. In two patients (7.7%), the age of vision loss could not be determined because it happened early in childhood. The remainder (69.2%) reported sequential decrease in acuity. In patients with sequential symptoms, the mean time to involvement of the second eye was 35.1 days (range 7 and 270 days).
The time to visual acuity stabilization was highly variable, with a mean of 7.8±8.1 months in those whose vision loss stabilized during the study time period. Eleven patients (42.3%) reported exposure to tobacco, alcohol, or drugs before the onset of symptoms. We did not find a statistically significant relationship between the consumption of alcohol, tobacco, and drugs and the manifestation of the disease in the sample of patients studied.
Of the 75 subjects with one of the three common mutations, 59 subjects (78.7%) had the m.11778G>A mutation, 12 subjects (16.0%) had the m.14484T>C mutation, and four subjects (5.3%) had the m.3460G>A mutation in this population (Table 1) .
Twelve families had Amerindian haplogroups: One family had the A2 haplogroup, four families had the B2i2 haplogroup, six families had the Cb haplogroup, and one family had the D1g haplogroup. One family had the J2b haplogroup, which is associated with European populations, and two families had the L1b haplogroup, which is associated with African populations (Table 2) .
Of the affected subjects, 92.3% had fractional visual acuity equal to or less than 0.1 (≥1.0 logMar) in the better eye. Only in two subjects of family 3 (m.11778G>A mutation and haplogroup C1b) did we observe fractional visual acuity better than 0.1 in the better eye.
In 83% of the affected patients, symmetric constriction of the pupil and no relative afferent pupillary defect were noted; in 17% of the affected patients, the pupillary light reflexes were present but remarkably slower. The visual field was altered in all patients, with central scotomas of varying intensity and size and cecocentral scotomas with concentric restriction of isopters.
Subjects with haplogroup C1b were more likely to retain 20/200 or better vision in the better eye than those with other haplogroups (p=0.033, Kruskal-Wallis). Subjects with the A2 haplogroup on average had later onset of disease (p=0.001, The following abbreviations were used; male (M), female (F), CF=counting fingers, HM=hand motions and LP=light perception.
ANOVA) than those with other haplogroups (47.3 years on average).
DISCUSSION
Molecular testing for LHON is not routinely performed in patients with optic atrophy in Chile. The 36 patients who were initially identified as candidates for molecular testing had undergone complete clinical testing performed by local neuroophthalmology departments and had been suspected of having LHON. We believe that the high pretest probability led to the high percentage of patients with a positive molecular test result. We did not further evaluate those with a negative molecular test for either the less frequent mutations associated with LHON or other genetic causes of optic atrophy.
Few studies have evaluated Amerindian mDNA haplogroups, either Central American or South American [26, 27, 32] . Studies of mDNAs in native Chilean populations (Mapuche, Pehuenche, and Yaghans), with a mixture of different ethnic groups and populations, have shown the following distribution by restriction fragment length polymorphism analysis and D-loop (control region) sequencing: 1.3% had haplogroup A, 8% haplogroup B, 43% haplogroup C, and 47.7% haplogroup D [26] . Another study of individuals from the admixed population of Santiago found that 8.1% had haplogroup A, 29% haplogroup B, 37.9% haplogroup C, and 25% haplogroup D [27] .
The number of cases in the study is small but given current prevalence estimates likely accounts for around 10% of the cases in Chile given the current population of 16.6 million [1, 3] . Due to the limited sample size, we are unable to make a formal assessment of the effect of haplogroup on penetrance and onset of disease. However, despite the relative lack of information regarding the overall accuracy of the described mDNA composition of the population in Chile, some authors suggest that Chilean populations are dominated by haplogroups C and D [26] . It is remarkable that in our study only one family out of 15 had haplogroup D, as haplogroup D is one of the most common in the Chilean population, with a frequency of 25% to 40% [26] and is the most prevalent in larger population samples from the Southern Cone of South America (Chile and Argentina) [32] . This could be a result of the relatively small population studied, but we cannot rule out that haplogroup D has a protective effect in carriers of LHON mutations similar to what has been noted with haplogroup H in European populations.
The penetrance across all families in this study was 61.8% for men and 12.2% for women. The gender ratio in this population was 4.2/1 with 21 men and five women affected, and 13 carrier men and 36 carrier women. The incomplete general penetrance and the gender ratio in this population are similar to those reported for other LHON populations around the world, with approximately 50% of men and approximately 10% of women affected [2, [45] [46] [47] [48] [49] [50] .
We also found that 92.3% of affected subjects had fractional visual acuity equal or less than 0.1. We did not observe any cases in which there was a meaningful recovery of vision, as reported by other authors [2] . In addition, no differences were observed in final visual acuity among the three mutations, which again may have been due to the relatively small number of patients.
In summary, haplogroup is one genetic factor suspected of modulating LHON. Recent studies suggest that haplogroups play an important role in the onset of LHON, and in particular, haplogroup and phylogenetic analyses suggest that one European-specific mDNA background plays a role in the expression of LHON by increasing the clinical penetrance of the primary mutations m.11778G>A and m.14484T>C. Because of the continent-specific distribution of mDNA haplogroups, there is a remarkable difference in these haplogroups, which may influence the expression of LHON in different ethnic groups. We find that there was a markedly decreased frequency of haplogroup D in Chilean subjects with LHON compared to what has been reported for the overall population. Future studies of populations with similar haplogroups could assist in providing support to the present findings and provide new clues on the molecular mechanism by which a particular mDNA background could influence clinical expression of LHON.
